Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Research expenses by Year
Research expenses (discovery & early preclinical) — Total ($M) ($M)
Vertex Pharmaceuticals Research expenses: $828M in FY2025, up 2.9% from a year earlier. That is the highest of the 13 years on record here.
Where the FY2025 figure comes from
“|| Total research expenses | $ 827.9 | 3% | $ 804.5 | 14% | $ 705.6”
Source: Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K MD&A & Note (Segment Significant Expenses).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up research expenses
- Research — Salary and employee benefits ($M)204 · FY2025
- Research — Stock-based compensation expense ($M)94.8 · FY2025
- Research — Outsourced services and other direct costs ($M)286 · FY2025
- Research — Infrastructure and facilities costs ($M)243 · FY2025
- Research — Collaborative & upfront licensing payments (FY2015–FY2021, $M)105 · FY2021
- Research — Outsourced services ex-lab supplies (FY2013–FY2018, $M)38.8 · FY2018
- Research — Laboratory supplies (standalone through FY2018, $M)50.6 · FY2018
Cite this data
StockData. (2026). Vertex Pharmaceuticals Research expenses ($M), annual FY2013–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-res-total
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.